257 related articles for article (PubMed ID: 34777239)
1. Clinical Characteristics and Management of Patients With McCune-Albright Syndrome With GH Excess and Precocious Puberty: A Case Series and Literature Review.
Zhai X; Duan L; Yao Y; Xing B; Deng K; Wang L; Feng F; Liang Z; You H; Yang H; Lu L; Chen S; Wang R; Pan H; Zhu H
Front Endocrinol (Lausanne); 2021; 12():672394. PubMed ID: 34777239
[TBL] [Abstract][Full Text] [Related]
2. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
Akintoye SO; Chebli C; Booher S; Feuillan P; Kushner H; Leroith D; Cherman N; Bianco P; Wientroub S; Robey PG; Collins MT
J Clin Endocrinol Metab; 2002 Nov; 87(11):5104-12. PubMed ID: 12414879
[TBL] [Abstract][Full Text] [Related]
3. Burosumab Therapy in a Paediatric Patient with McCune-Albright Syndrome: A Case Report.
Apperley LJ; Senniappan S
Horm Res Paediatr; 2023; 96(3):341-348. PubMed ID: 36279852
[TBL] [Abstract][Full Text] [Related]
4. McCune-Albright Syndrome: A Case Report and Review of Literature.
Nicolaides NC; Kontou M; Vasilakis IA; Binou M; Lykopoulou E; Kanaka-Gantenbein C
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239810
[TBL] [Abstract][Full Text] [Related]
5. [McCune-Albright syndrome revealed by Blaschko-linear café-au-lait spots on the back].
Jung AJ; Soskin S; Paris F; Lipsker D
Ann Dermatol Venereol; 2016 Jan; 143(1):21-6. PubMed ID: 26610360
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and management of growth hormone excess in patients with McCune-Albright syndrome.
Yao Y; Liu Y; Wang L; Deng K; Yang H; Lu L; Feng F; Xing B; You H; Jin Z; Wang R; Pan H; Chen S; Zhu H
Eur J Endocrinol; 2017 Mar; 176(3):295-303. PubMed ID: 28007843
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of precocious puberty in atypical presentations of McCune-Albright syndrome: a case series review.
Bercaw-Pratt JL; Moorjani TP; Santos XM; Karaviti L; Dietrich JE
J Pediatr Adolesc Gynecol; 2012 Feb; 25(1):e9-e13. PubMed ID: 22051789
[TBL] [Abstract][Full Text] [Related]
8. Clinical and endocrine characteristics and genetic analysis of Korean children with McCune-Albright syndrome: a retrospective cohort study.
Cho EK; Kim J; Yang A; Ki CS; Lee JE; Cho SY; Jin DK
Orphanet J Rare Dis; 2016 Aug; 11(1):113. PubMed ID: 27506760
[TBL] [Abstract][Full Text] [Related]
9. McCune-Albright syndrome: growth hormone and prolactin hypersecretion.
Christoforidis A; Maniadaki I; Stanhope R
J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():623-5. PubMed ID: 16789626
[TBL] [Abstract][Full Text] [Related]
10. McCune-Albright syndrome.
Dumitrescu CE; Collins MT
Orphanet J Rare Dis; 2008 May; 3():12. PubMed ID: 18489744
[TBL] [Abstract][Full Text] [Related]
11. McCune-Albright syndrome and type 1 diabetes mellitus: a novel presentation.
Chatty P; Khattab A; Marshall I
Ann N Y Acad Sci; 2020 Mar; 1463(1):5-8. PubMed ID: 32037600
[TBL] [Abstract][Full Text] [Related]
12. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
Feuillan PP; Foster CM; Pescovitz OH; Hench KD; Shawker T; Dwyer A; Malley JD; Barnes K; Loriaux DL; Cutler GB
N Engl J Med; 1986 Oct; 315(18):1115-9. PubMed ID: 3093862
[TBL] [Abstract][Full Text] [Related]
13. Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone?
Hannon TS; Noonan K; Steinmetz R; Eugster EA; Levine MA; Pescovitz OH
J Pediatr; 2003 May; 142(5):532-8. PubMed ID: 12756386
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome: patient report and literature review.
Sawathiparnich P; Osuwanaratana P; Santiprabhob J; Likitmaskul S
J Pediatr Endocrinol Metab; 2006 Jan; 19(1):81-6. PubMed ID: 16509532
[TBL] [Abstract][Full Text] [Related]
16. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome.
Leet AI; Chebli C; Kushner H; Chen CC; Kelly MH; Brillante BA; Robey PG; Bianco P; Wientroub S; Collins MT
J Bone Miner Res; 2004 Apr; 19(4):571-7. PubMed ID: 15005844
[TBL] [Abstract][Full Text] [Related]
17. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
Feuillan PP; Jones J; Cutler GB
J Clin Endocrinol Metab; 1993 Sep; 77(3):647-51. PubMed ID: 8370686
[TBL] [Abstract][Full Text] [Related]
18. Extent of Extraskeletal Manifestations of Fibrous Dysplasia/McCune-Albright Syndrome in Patients with Mazabraud's Syndrome.
Hagelstein-Rotman M; Appelman-Dijkstra NM; Boyce AM; Chapurlat R; Dur NBJ; Gensburger D; Majoor BCJ; van de Sande MAJ; Dijkstra PDS
Calcif Tissue Int; 2022 Mar; 110(3):334-340. PubMed ID: 34854944
[TBL] [Abstract][Full Text] [Related]
19. [McCune-Albright syndrome with hyperthyroidism: report of one case and review of literature].
Chen QM; Meng J
Shanghai Kou Qiang Yi Xue; 2018 Aug; 27(4):445-448. PubMed ID: 30483720
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome.
Estrada A; Boyce AM; Brillante BA; Guthrie LC; Gafni RI; Collins MT
Eur J Endocrinol; 2016 Nov; 175(5):477-483. PubMed ID: 27562402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
